Discovery of 5-Nitro-N-(3-(trifluoromethyl)phenyl) Pyridin-2-amine as a Novel Pure Androgen Receptor Antagonist against Antiandrogen Resistance
Lists
Only you see this
Abstract
The transformation of clinical androgen receptor (AR) antagonists into agonists driven by AR mutations poses a significant challenge in treating prostate cancer (PCa). Novel anti-AR therapeutics combating mutation-induced resistance are required. Herein, by combining structure-based virtual screening and biological evaluation, a high-affinity agonist <b>E10</b> was first discovered. Then guided by the representative conformation of State 1 at the free energy landscape, the structural optimization of <b>E10</b> was performed, and pure AR antagonists <b>EL15</b> (IC<sub>50</sub> = 0.94 μM) and <b>EF2</b> (IC<sub>50</sub> = 0.30 μM) were successfully identified. Both can antagonize wild-type and variant drug-resistant ARs. Therein, <b>EF2</b> demonstrated potent inhibition of the AR pathway and effectively suppressed tumor growth in a C4-2B xenograft mouse model following oral administration. Further molecular dynamics simulation and mutagenesis studies revealed atomic insights into the mode of action of <b>EF2</b> which may serve as a novel lead compound for developing therapeutics against AR-driven PCa.
BibTeX
@article{wang2024discovery,
author = {Huating Wang and Xuwen Wang and Haiyang Zhong and Lvtao Cai and Weitao Fu and Xin Chai and Jianing Liao and Rong Sheng and Luhu Shan and Xiaohong Xu and Lei Xu and Peichen Pan and Tingjun Hou and Dan Li},
title = {{Discovery of 5-Nitro-<i>N</i>-(3-(trifluoromethyl)phenyl) Pyridin-2-amine as a Novel Pure Androgen Receptor Antagonist against Antiandrogen Resistance}},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01970},
}Loading related content...